🥇 First rule of investing? Know when to save! Up to 55% off InvestingPro before BLACK FRIDAYCLAIM SALE

REFILE-UPDATE 2-British stocks drop as prospect of no-deal Brexit grows

Published 12/11/2020, 04:52 PM
Updated 12/12/2020, 01:20 AM
© Reuters.
UK100
-
BP
-
SASY
-
RDSa
-
GSK
-
RR
-
FTMC
-
FTNMX301010
-
FTNMX601010
-

(Updates quote in first bullet point)
* PM Johnson says chances of no-deal Brexit "very, very
likely"
* GSK muted on signalling vaccine delay
* Rolls-Royce tumbles on deepening 2020 cash outflow
forecast
* FTSE 100 down 0.8%, FTSE 250 off 0.7%

By Sagarika Jaisinghani and Shashank Nayar
Dec 11 (Reuters) - London-listed shares ended lower on
Friday as investors prepared for Britain to leave the European
Union in three weeks without a trade deal, while Rolls-Royce
tumbled after it downgraded this year's forecast.
The blue-chip FTSE 100 .FTSE shed 0.8%, with energy
.FTNMX0530 and banking stocks .FTNMX8350 leading declines.
Oil majors BP BP.L and Royal Dutch shell RDSa.L were the
biggest drags on the index.
The domestically-focused FTSE 250 .FTMC slipped 0.7%,
bringing weekly declines to nearly 3%, after British Prime
Minister Boris Johnson said that it was "very, very likely" that
trade talks with the European Union would fail and that the UK
would leave the bloc at the end of year without a
deal. The FTSE 250 would slide between 6%-10% and UK bank shares
would drop 10%-20% with a no-trade deal Brexit, Morgan Stanley
strategists said. "The increasing likelihood of a no-deal Brexit at the end of
the year has definitely dampened mood in the near term, but
investors continue to price for a last minute arrangement or
further talks even after the year-end deadline," said Andrea
Cicione, a strategist at TS Lombard.
German Foreign Minister Heiko Maas said that Britain and EU
may have to continue negotiations to complete a deal beyond a
deadline set for Sunday and that the talks will not fail as a
few more days of discussions are needed. London's benchmark stock indexes have bounced since a
coronavirus-driven crash in March, but have lagged their U.S.
and European peers as data suggests a much deeper impact on
domestic economic growth.
A Reuters poll this month found it will take at least two
years for UK GDP to reach pre-pandemic levels. In company news, drugmaker GlaxoSmithKline GSK.L dropped
0.3% as it said the experimental vaccine it was developing with
France's Sanofi SASY.PA showed an insufficient immune response
in clinical trials. Rolls-Royce RR.L tumbled 7.9% as it deepened this year's
cash outflow forecast and warned the outlook remained
challenging.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.